Literature DB >> 29693888

Prognostic value of preoperative neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with epithelial ovarian cancer.

Y Yildiz, Y Kucukzeybek, A Alacacioglu, U Varol, I Yildiz, M Akyol, G Kabadayι, H Taskaynatan, T Salman, V Bayoglu, U Oflazoglu, M O Tarhan.   

Abstract

PURPOSE: The neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) have recently been evaluated in many cancers in prediction of survival outcomes. The purpose of this study was to investigate the impact of NLR and PLR on the prognosis of patients with epithelial ovarian cancer (EOC).
MATERIALS AND METHODS: A total of 208 patients with EOC were included in the study. Hematological parameters and clinicopathological data during diagnosis were retrospectively evaluated. The cut-off values were determined by calculating receiver operating characteristic (ROC) curve analysis of the patients.
RESULTS: The median over-all survival (OS) of patients with low NLR was 69 months (95% CI, 43.0-94.9) whereas high NLR was 36 months (95% CI, 29.1-42.8). The median OS with low PLR patients was 76 months (95% CI, 46.4-105.5) and high PLR was 35 months (95% CI, 28.5-41.4). In serous tumors (70.7%), the median OS with low NLR and high NLR was 54 months (95% CI, 27.9-80.0) and 34 months (95% CI, 28.2-39.7), and for the median OS with low PLR and high PLR it was 51 months (95% CI, 2 1.2-80.7) and 35 months (95% CI, 27.8-42.1), respectively.
CONCLUSION: The present findings showed that the high NLR and high PLR were associated with poor prognosis and these values are significantly remarkable in EOC patients.

Entities:  

Mesh:

Year:  2017        PMID: 29693888

Source DB:  PubMed          Journal:  Eur J Gynaecol Oncol        ISSN: 0392-2936            Impact factor:   0.196


  4 in total

1.  [Impact of the Pretreatment or Posttreatment NLR and PLR on the Response of First Line Chemotherapy and the Outcomes in Patients with Advanced Non-small Cell Lung Cancer].

Authors:  Fumei Yi; Yangchun Gu; Sen Chen; Yan'e Liu; Wencheng Yin; Yu Zhang; Baoshan Cao
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2018-06-20

2.  The Efficacy of Different Inflammatory Markers for the Prognosis of Patients with Malignant Tumors.

Authors:  Kaiwen Zheng; Xiangliang Liu; Wei Ji; Jin Lu; Jiuwei Cui; Wei Li
Journal:  J Inflamm Res       Date:  2021-11-03

3.  Neutrophil-to-lymphocyte ratio and chemotherapy response score as prognostic markers in ovarian cancer patients treated with neoadjuvant chemotherapy.

Authors:  M Liontos; A Andrikopoulou; K Koutsoukos; C Markellos; E Skafida; O Fiste; M Kaparelou; N Thomakos; D Haidopoulos; A Rodolakis; M A Dimopoulos; F Zagouri
Journal:  J Ovarian Res       Date:  2021-11-01       Impact factor: 4.234

4.  Study on the Application of Systemic Inflammation Response Index and Platelet-Lymphocyte Ratio in Ovarian Malignant Tumors.

Authors:  Huifang Huang; Kunhai Wu; Lufei Chen; Xiaomei Lin
Journal:  Int J Gen Med       Date:  2021-12-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.